image
IM Cannabis Corp. IMCC
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IL
Watchlist
$ 2.81
-0.355 %
$ 6.27 M
Market Cap
-0.62
P/E
1. INTRINSIC VALUE

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.[ Read More ]

The intrinsic value of one IMCC stock under the base case scenario is HIDDEN Compared to the current market price of 2.81 USD, IM Cannabis Corp. is HIDDEN

IMCC Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart IMCC

image
FINANCIALS
48.8 M REVENUE
-10.18%
Growth Rates
1Year -10.18%
3Years 45.36%
5Years 56.51%
7Years 0.00%
10Years 0.00%
-12.8 M OPERATING INCOME
51.56%
Growth Rates
1Year 51.56%
3Years -15.77%
5Years -38.79%
7Years -161.62%
10Years -50.20%
-10.2 M NET INCOME
94.65%
Growth Rates
1Year 94.65%
3Years 29.13%
5Years -142.22%
7Years -152.22%
10Years -45.47%
-8.08 M OPERATING CASH FLOW
36.12%
Growth Rates
1Year 36.12%
3Years -0.65%
5Years -180.80%
7Years 0.00%
10Years -58.08%
-1.18 M INVESTING CASH FLOW
16.05%
Growth Rates
1Year 16.05%
3Years 33.80%
5Years -10.15%
7Years 0.00%
10Years 0.00%
9.42 M FINANCING CASH FLOW
97.75%
Growth Rates
1Year 97.75%
3Years 11.79%
5Years 160.02%
7Years 0.00%
10Years 62.48%
14.8 M REVENUE
22.27%
Growth Rates
1Year -10.18%
3Years 45.36%
5Years 56.51%
7Years 0.00%
10Years 0.00%
2.87 M OPERATING INCOME
150.96%
Growth Rates
1Year 51.56%
3Years -15.77%
5Years -38.79%
7Years -161.62%
10Years -50.20%
-3.03 M NET INCOME
46.13%
Growth Rates
1Year 94.65%
3Years 29.13%
5Years -142.22%
7Years -152.22%
10Years -45.47%
387 K OPERATING CASH FLOW
136.07%
Growth Rates
1Year 36.12%
3Years -0.65%
5Years -180.80%
7Years 0.00%
10Years -58.08%
-396 K INVESTING CASH FLOW
-19700.00%
Growth Rates
1Year 16.05%
3Years 33.80%
5Years -10.15%
7Years 0.00%
10Years 0.00%
1.5 M FINANCING CASH FLOW
466.42%
Growth Rates
1Year 97.75%
3Years 11.79%
5Years 160.02%
7Years 0.00%
10Years 62.48%
Balance Sheet Decomposition IM Cannabis Corp.
image
Current Assets 24.3 M
Cash & Short-Term Investments 1.81 M
Receivables 11.3 M
Other Current Assets 11.1 M
Non-Current Assets 24.5 M
Long-Term Investments 2.28 M
PP&E 6.36 M
Other Non-Current Assets 15.9 M
Current Liabilities 32.8 M
Accounts Payable 9.22 M
Short-Term Debt 12.6 M
Other Current Liabilities 11 M
Non-Current Liabilities 2.3 M
Long-Term Debt 1.21 M
Other Non-Current Liabilities 1.1 M
EFFICIENCY
Earnings Waterfall IM Cannabis Corp.
image
Revenue 48.8 M
Cost Of Revenue 39 M
Gross Profit 9.85 M
Operating Expenses 22.6 M
Operating Income -12.8 M
Other Expenses -2.56 M
Net Income -10.2 M
RATIOS
20.17% GROSS MARGIN
20.17%
Averages
1Year 20.17%
3Years 18.67%
5Years 33.04%
7Years 44.25%
10Years 30.98%
-26.21% OPERATING MARGIN
-26.21%
Averages
1Year -26.21%
3Years -48.50%
5Years -54.12%
7Years -30.59%
10Years -21.41%
-19.46% NET MARGIN
-19.46%
Averages
1Year -19.46%
3Years -33.14%
5Years -72.40%
7Years -47.50%
10Years -33.25%
-65.64% ROE
-65.64%
Averages
1Year -65.64%
3Years -61.62%
5Years -94.78%
7Years -179.87%
10Years -125.99%
-19.46% ROA
-19.46%
Averages
1Year -19.46%
3Years -22.32%
5Years -33.27%
7Years 430.72%
10Years -1945.20%
-51.27% ROIC
-51.27%
Averages
1Year -51.27%
3Years -49.39%
5Years -50.08%
7Years -195.97%
10Years -137.31%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis IM Cannabis Corp.
image
Net Income -10.2 M
Depreciation & Amortization 3 M
Capital Expenditures -581 K
Stock-Based Compensation 225 K
Change in Working Capital 1.4 M
Others -3.75 M
Free Cash Flow -8.66 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets IM Cannabis Corp.
image
IMCC has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION

Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally.

image
-0.36 USD
CLVR
Overvalued 359880.08%

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

image
0 USD
BFRI
Overvalued 100.00%

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China.

image
7.69 USD
UPC
Undervalued 5366.36%

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name.

image
0.215 USD
IXHL
Overvalued 89.26%

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States.

image
-0.753 USD
PAHC
Overvalued 103.08%

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

image
91.3 USD
SUPN
Undervalued 156.69%
6. Ownership
Insider Ownership IM Cannabis Corp.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
IM Cannabis Corp. (IMCC) Q3 2024 Earnings Call Transcript IM Cannabis Corp. (NASDAQ:IMCC ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Anna Taranko - Director of Investor and Public Relations Oren Shuster - Chief Executive Officer Uri Birenberg - Chief Financial Officer Conference Call Participants Operator Good morning, and welcome to IM Cannabis' Third Quarter 2024 Earnings Conference Call. Today's conference call is being recorded. seekingalpha.com - 2 days ago
IM Cannabis Reports Third Quarter Financial Results IMC pairs a +12% increase in revenue with a -16% decrease in the total operating expenses, building a solid foundation to deliver in 2025. TORONTO and GLIL YAM, Israel , Nov. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the third quarter ended September 30, 2024. prnewswire.com - 2 days ago
IM Cannabis to Report Third Quarter 2024 Financial Results on Thursday, November 14th at 9:00am ET TORONTO and GLIL YAM, Israel , Nov. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the third 2024 ended September 30, 2024, on November 14, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. prnewswire.com - 1 week ago
IM Cannabis Announces up to US$1,613,000 Private Placement Offering Led by Management THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO and GLIL YAM, Israel , Oct. 4, 2024 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that it intends to undertake a non-brokered private placement offering of up to US$1,613,000 through the sale of approximately 625,000 units (each, an "Unit") at a price per Unit (the "Offering Price") calculated on the basis of the deemed price per common shares in the capital of the Company (each, a "Share") equal to the 10-day volume weighted average price of the Shares on Canadian Securities Exchange (the "Exchange") ending on the trading day preceding October 3, 2024. Each Unit will be comprised of one Share and one Share purchase warrant (each, a "Warrant"). prnewswire.com - 1 month ago
IMC Germany Announces Outstanding Preliminary Q3, 2024 Performance with 50% Growth Over Q2 TORONTO and GLIL YAM, Israel , Oct. 2, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that the preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH ("IMC Germany"), for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50% increase in revenue compared to the second quarter, where IMC Germany sold about CAD$ 3.5M. This outstanding growth demonstrates IMC Germany's successful execution of its strategic initiatives and strong market demand for its products. prnewswire.com - 1 month ago
IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors TORONTO and GLIL YAM, Israel , Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. prnewswire.com - 2 months ago
IM Cannabis Corp. (IMCC) Q2 2024 Earnings Call Transcript IM Cannabis Corp. (NASDAQ:IMCC ) Q2 2024 Earnings Conference Call August 14, 2024 9:00 AM ET Company Participants Anna Taranko - Director of Investor and Public Relations Oren Shuster - Chief Executive Officer Uri Birenberg - Chief Financial Officer Conference Call Participants Scott Fortune - ROTH MKM Aaron Grey - Alliance Global Partners Operator Good morning, and welcome to IM Cannabis' Second Quarter 2024 Earnings Conference Call. Today's conference call is being recorded. seekingalpha.com - 3 months ago
IM Cannabis Corp. (IMCC) Reports Q2 Loss, Tops Revenue Estimates IM Cannabis Corp. (IMCC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.14 per share a year ago. zacks.com - 3 months ago
IM Cannabis Reports Second Quarter Financial Results IMC Germany delivers +200% in sales in first three months after German legalization, while overall revenue grows 12% vs Q2 2023 TORONTO and GLIL YAM, Israel, Aug. 14, 2024 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2023, unless otherwise stated. prnewswire.com - 3 months ago
IM Cannabis to Report Second Quarter 2024 Financial Results on Wednesday, August 14th at 9:00am ET TORONTO and GLIL YAM, Israel , Aug. 6, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2024 ended June 30, 2024, on Wednesday, August 14, 2024, before the market opens. The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. prnewswire.com - 3 months ago
IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement TORONTO and GLIL YAM, Israel , July 29, 2024 /PRNewswire/ -- IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced that on July 26, 2024, it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the "Minimum Bid Price Requirement"). IMC is now in compliance with all applicable listing standards and will continue to be listed and traded on the NASDAQ Stock Market. prnewswire.com - 3 months ago
IM Cannabis Shares Surge 586% After 6:1 Consolidation: What Investors Need To Know IM Cannabis Corp. IMCC, a leading medical marijuana company announced that its common shares are trading on a 6:1 post-consolidated basis. benzinga.com - 4 months ago
8. Profile Summary

IM Cannabis Corp. IMCC

image
COUNTRY IL
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 6.27 M
Dividend Yield 0.00%
Description IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers cannabis flowers and strain specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, and pressed hash offerings under the WAGNERS and Highland Grow brands. The company serves medical patients and adult-use recreational consumers. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Contact Kibbutz Glil Yam, Tel Aviv, 4690500 https://www.imcannabis.com
IPO Date May 20, 2020
Employees 95
Officers Mr. Oren Shuster Chief Executive Officer & Director Mr. Uri Birenberg Chief Financial Officer Mr. Richard Balla Chief Executive Officer of Adjupharm Anna Taranko Director Investor & Public Relations Advocate Michal Lebovitz Nissimov General Counsel